Concordance between Three Homologous Recombination Deficiency (HRD) Assays in Patients with High-Grade Epithelial Ovarian Cancer.
biomarker
concordance
enomic instability
epithelial ovarian cancer
homologous recombination deficiency
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Nov 2023
22 Nov 2023
Historique:
received:
27
09
2023
revised:
08
11
2023
accepted:
16
11
2023
medline:
9
12
2023
pubmed:
9
12
2023
entrez:
9
12
2023
Statut:
epublish
Résumé
Our aim was to evaluate the concordance between the Myriad MyChoice and two alternative homologous recombination deficiency (HRD) assays (AmoyDx HRD Focus NGS Panel and OncoScan™) in patients with epithelial ovarian cancer (EOC). Tissue samples from 50 patients with newly diagnosed EOC and known Myriad MyChoice HRD status were included. DNA aliquots from tumor samples, previously evaluated with Myriad MyChoice and centrally reassessed, were distributed to laboratories to assess their HRD status using the two platforms, after being blinded for the Myriad MyChoice CDx HRD status. The primary endpoint was the concordance between Myriad MyChoice and each alternative assay. Tumor samples were evaluated with an AmoyDx
Identifiants
pubmed: 38067228
pii: cancers15235525
doi: 10.3390/cancers15235525
pmc: PMC10705222
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : AstraZeneca (Hellas)
ID : NA
Organisme : Hellenic Cooperative Oncology Group
ID : NA
Références
Ann Oncol. 2015 Jan;26(1):64-70
pubmed: 25319062
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16910-5
pubmed: 20837533
Cancer Genet. 2018 Jan;220:1-12
pubmed: 29310832
Breast Cancer Res Treat. 2012 Jul;134(1):353-62
pubmed: 22434525
Br J Cancer. 2012 Nov 6;107(10):1776-82
pubmed: 23047548
Oncotarget. 2013 Nov;4(11):1868-81
pubmed: 24240121
Cell. 2007 Jan 12;128(1):157-70
pubmed: 17218262
Cancer. 2019 Aug 15;125(16):2772-2781
pubmed: 31154673
Cancer Discov. 2015 Nov;5(11):1137-54
pubmed: 26463832
Oncol Lett. 2023 Sep 22;26(5):480
pubmed: 37809048
Obstet Gynecol. 2006 Sep;108(3 Pt 1):521-8
pubmed: 16946210
Cancer Genomics Proteomics. 2023 Sep-Oct;20(5):448-455
pubmed: 37643779
Cancers (Basel). 2022 Dec 21;15(1):
pubmed: 36612041
Clin Genet. 2014 Jan;85(1):36-42
pubmed: 24010542
Cancer Res. 2012 Nov 1;72(21):5454-62
pubmed: 22933060
Breast Cancer Res. 2014 Dec 05;16(6):475
pubmed: 25475740
BMC Bioinformatics. 2013;14 Suppl 11:S1
pubmed: 24564169
Biom J. 2008 Jun;50(3):419-30
pubmed: 18435502
Clin Cancer Res. 2023 Aug 15;29(16):3124-3129
pubmed: 37067532
Biomolecules. 2023 Oct 03;13(10):
pubmed: 37892162
BJOG. 2022 Nov;129 Suppl 2:14-22
pubmed: 36485068
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
Am J Clin Oncol. 2023 Sep 1;46(9):414-419
pubmed: 37314974
BMC Bioinformatics. 2017 May 31;18(1):286
pubmed: 28569140
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Cancer Discov. 2012 Apr;2(4):366-375
pubmed: 22576213
Oncotarget. 2016 May 31;7(22):32731-53
pubmed: 27129168
J Clin Oncol. 2020 Apr 10;38(11):1164-1174
pubmed: 32073956
Pathologica. 2022 Aug;114(4):288-294
pubmed: 36136896
BMC Cancer. 2019 Jun 3;19(1):535
pubmed: 31159747
Int J Cancer. 2020 Sep 1;147(5):1334-1342
pubmed: 32022259
JAMA Oncol. 2022 Nov 1;8(11):1579-1587
pubmed: 36074460
J Med Genet. 2020 Jan;57(1):53-61
pubmed: 31300551
BMC Cancer. 2022 Dec 14;22(1):1310
pubmed: 36517748
Bioinformatics. 2021 Jul 27;37(13):1909-1911
pubmed: 32449758
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
Breast Cancer Res Treat. 2019 Apr;174(3):627-637
pubmed: 30607631